Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02978235 · ClinicalTrials.gov registry record · Phase 1
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
A Phase 1 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02978235 is a Phase 1 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 11 participants.
The verdict
NCT02978235, a Phase 1 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.
Interventions
- DRUG TAS4464
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2018-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02978235
The ClinicalTrials.gov registry entry for NCT02978235 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS4464 is the first listed.
NCT02978235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02978235 about?
NCT02978235 is a clinical study titled "A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma". The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.
What is the current status of trial NCT02978235?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-03-01. Estimated completion is 2018-02-01.
What interventions are being tested in trial NCT02978235?
The interventions under investigation include: TAS4464 (DRUG).
Who is sponsoring clinical trial NCT02978235?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.